{"entity":{"id":"nct07229612","kind":"trial","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-4298 Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07229612 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 200 participants planned, started 2025-12-03 and due to reach its primary completion in 2028-11. Interventions recorded: SHR-4298 Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07229612","url":"https://clinicaltrials.gov/study/NCT07229612"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07229612","phase":"1/2","setting":"A Multicenter, Open-label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4298 Injection in Patients With Malignant Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":200,"outcomes":[]},"route":"/trials/nct07229612/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}